Cutaneous T-cell lymphoma (CTCL) remains one of the most challenging cancers to diagnose and treat, particularly in its early stages. Soligenix Inc. (NASDAQ: SNGX) is targeting these critical gaps with its novel therapeutic approach, HyBryte (synthetic hypericin), a visible light-activated photodynamic therapy designed for early-stage CTCL. Unlike traditional ultraviolet-based phototherapies that carry long-term safety risks with cumulative exposure, HyBryte is activated by visible light in the red-yellow spectrum, allowing targeted treatment of malignant T-cells in the skin while minimizing damage to surrounding healthy tissue.
Clinical data reported by Soligenix indicate that HyBryte has demonstrated statistically significant efficacy in reducing CTCL lesions in patients with early-stage disease. With the successful completion of the second Phase 3 study, the company is poised to seek regulatory approvals for commercialization worldwide. This advancement is particularly important given the limited treatment options available for CTCL and the potential for HyBryte to offer a safer alternative to current therapies.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs. Beyond HyBryte, the company's Specialized BioTherapeutics segment is also exploring the expansion of synthetic hypericin into psoriasis (SGX302) and developing first-in-class innate defense regulator technology, dusquetide (SGX942), for inflammatory diseases such as oral mucositis in head and neck cancer and Behçet's disease (SGX945). The company's Public Health Solutions segment includes vaccine programs for ricin toxin (RiVax), filoviruses, and COVID-19 (CiVax), leveraging its proprietary ThermoVax heat stabilization platform.
For further information on Soligenix and its pipeline, visit the company's website at www.Soligenix.com. The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.
